Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Data from this safety trial phase are anticipated to be announced in May. The study also includes assessments of biomarkers including cortisol levels before and after treatment.NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. This marks a significant milestone with the enrollment of 30 subjects across five cohorts, receiving doses up to 1,000 micrograms.
紐約州紐約/ACCESSWIRE/2024年5月1日/生物製藥創新的領導者Protagenic Therapeutics, Inc.（納斯達克股票代碼：PTIX）今天宣佈，其1期試驗的單劑量部分已完成註冊，該試驗涉及其合成壓力調節肽 PT00114，用於治療神經精神疾病。這標誌着一個重要的里程碑，共招收了五個群組的30名受試者，接受的劑量高達1,000微克。
PT00114 has demonstrated outstanding tolerability with no adverse safety findings, building upon safety validations reported earlier this year. The trial progresses as PT00114 shows potential to transform treatment for anxiety, depression, PTSD, and addiction.
在今年早些時候報告的安全驗證基礎上，PT00114 表現出卓越的耐受性，沒有不良的安全發現。隨着 PT00114 顯示出改變焦慮、抑鬱、創傷後應激障礙和成癮治療方法的潛力，該試驗正在取得進展。
"Completing this phase is an important step toward developing a safe, effective therapy for those affected by severe stress-related conditions," stated Dr. Maurizio Fava, Psychiatrist-in-Chief at Massachusetts General Hospital and Principal Investigator of the study.
麻省綜合醫院首席精神科醫生、該研究的首席研究員毛裏齊奧·法瓦博士說：“完成這一階段是爲受嚴重壓力相關疾病影響的人開發安全、有效的治療方法的重要一步。”
Data from this safety trial phase are anticipated to be announced in May. The study also includes assessments of biomarkers including cortisol levels before and after treatment.
該安全試驗階段的數據預計將於5月公佈。該研究還包括對生物標誌物的評估，包括治療前後的皮質醇水平。
Protagenic Therapeutics continues to lead in the development of neuro-active peptides, addressing the profound need for innovative treatments in mental health.
Protagenic Therapeutics繼續在神經活性肽的開發方面處於領先地位，滿足了心理健康對創新療法的迫切需求。
For more details, visit .
欲了解更多詳情，請訪問。
About PT00114:
PT00114 is a candidate to become a therapeutic for severe neuropsychiatric conditions, mimicking the naturally occurring brain peptide TCAP to counteract stress-induced hormonal effects.
關於 PT00114：
PT00114 模仿天然存在的大腦肽 TCAP 來抵消壓力引起的荷爾蒙效應，是治療嚴重神經精神疾病的候選藥物。
Forward-Looking Statements:
Statements in this release about future expectations are "forward-looking" and subject to risks and uncertainties. Investors are cautioned against placing undue reliance on such statements.
前瞻性陳述：
本新聞稿中關於未來預期的陳述是 “前瞻性的”，受風險和不確定性的影響。提醒投資者不要過分依賴此類聲明。
Company Contact:
Alexander K. Arrow, MD, CFA
, Chief Financial Officer
, Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342
Email: alex.arrow@protagenic.com
公司聯繫人：
亞歷山大·阿羅，醫學博士，特許金融分析師
，首席財務官
，Protagenic Therapeutics, Inc. 第五大道 149 號，套房 500，紐約，紐約州 10010。電話：213-260-4342
電子郵件：alex.arrow@protagenic.com
Investor Relations Contact:
Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com
投資者關係聯繫人：
Kirin M. Smith，PCG Advisory, Inc. 總裁。第三大道950號，套房 #2700，紐約，紐約州，10022。電話：646-823-8656 電子郵件：ksmith@pcgadvisory.com
SOURCE: Protagenic Therapeutics, Inc.
來源：Protagenic Therapeutics, Inc.
譯文內容由第三人軟體翻譯。
